Metabonomics Characteristics and Predictive Value for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease

wenbinlu1 site in 1 country300 target enrollmentAugust 1, 2020

ConditionsNeurocognitive Disorders

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Neurocognitive Disorders
Sponsor: wenbinlu
Enrollment: 300
Locations: 1
Primary Endpoint: the level of metabolomics in patients' blood sample
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Perioperative neurocognitive disorders(PND) is common to see in elderly patients. Although PND increases patient mortality as well as hospitalization time, apparent inflammatory factors, and related mechanisms are still unknown. Metabolites could reveal chemical fingerprints left behind by cellular processes, which in turn provide a new aspect to understand the biological process behind. we aim to found the metabolomics can aid the development of diagnostic markers of PND screening, early detection, and further, provide a basis for disease prevention and treatment.

Registry

clinicaltrials.gov

Start Date

August 1, 2020

End Date

December 1, 2022

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

wenbinlu

Responsible Party

Sponsor Investigator

Principal Investigator

wenbinlu

Principal Investigator

Changhai Hospital

Eligibility Criteria

Inclusion Criteria

•Parkinson's patients undergoing elective deep brain stimulation
•Age ≥55 years
•ASA physical statusⅠ-Ⅲ
•Elementary school or above

Exclusion Criteria

•patients with ASA physical status\>III
•patients with systemic immune diseases, hematological diseases (hematological tumors or leukemia), patients after transplantation, malignant tumors
•patients with metabolic diseases such as diabetes, ketoacidosis, hyperosmolar syndrome, long-term hypoglycemia,gout
•patients who refused to join the study and lost to follow-up